1. Home
  2. PODD vs EG Comparison

PODD vs EG Comparison

Compare PODD & EG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • EG
  • Stock Information
  • Founded
  • PODD 2000
  • EG 1973
  • Country
  • PODD United States
  • EG Bermuda
  • Employees
  • PODD N/A
  • EG N/A
  • Industry
  • PODD Medical/Dental Instruments
  • EG Property-Casualty Insurers
  • Sector
  • PODD Health Care
  • EG Finance
  • Exchange
  • PODD Nasdaq
  • EG Nasdaq
  • Market Cap
  • PODD 16.5B
  • EG 16.0B
  • IPO Year
  • PODD 2007
  • EG 1995
  • Fundamental
  • Price
  • PODD $261.71
  • EG $354.85
  • Analyst Decision
  • PODD Buy
  • EG Buy
  • Analyst Count
  • PODD 16
  • EG 9
  • Target Price
  • PODD $265.81
  • EG $428.44
  • AVG Volume (30 Days)
  • PODD 528.9K
  • EG 429.8K
  • Earning Date
  • PODD 11-07-2024
  • EG 02-05-2025
  • Dividend Yield
  • PODD N/A
  • EG 2.26%
  • EPS Growth
  • PODD 235.68
  • EG 18.07
  • EPS
  • PODD 5.74
  • EG 63.93
  • Revenue
  • PODD $1,983,900,000.00
  • EG $16,436,500,000.00
  • Revenue This Year
  • PODD $23.56
  • EG N/A
  • Revenue Next Year
  • PODD $18.07
  • EG $6.72
  • P/E Ratio
  • PODD $45.91
  • EG $5.56
  • Revenue Growth
  • PODD 27.42
  • EG 16.15
  • 52 Week Low
  • PODD $160.19
  • EG $343.76
  • 52 Week High
  • PODD $279.77
  • EG $407.30
  • Technical
  • Relative Strength Index (RSI)
  • PODD 46.07
  • EG 30.92
  • Support Level
  • PODD $258.96
  • EG $352.41
  • Resistance Level
  • PODD $279.77
  • EG $367.63
  • Average True Range (ATR)
  • PODD 6.52
  • EG 5.94
  • MACD
  • PODD -1.90
  • EG -2.52
  • Stochastic Oscillator
  • PODD 4.61
  • EG 5.36

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

About EG Everest Group Ltd.

Everest Group Ltd is engaged in providing insurance services in the U.S., Bermuda, and international markets. It operates in Reinsurance and Insurance business. The Reinsurance operation writes property and casualty reinsurance and specialty lines of business, on both a treaty and facultative basis, through reinsurance brokers, as well as directly with ceding companies. The Insurance operation writes property and casualty insurance directly and through brokers, surplus lines brokers, and general agents within the U.S., Bermuda, Canada, Europe, and South America.

Share on Social Networks: